177Lu-DOTA-TATE

DRUG2 trials

Sponsors

Lund University Hospital, Peking Union Medical College Hospital

Conditions

Liver MetastasesNeuroendocrine Tumors

Phase 1

Treatment Using 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors

Peking Union Medical College HospitalNeuroendocrine Tumors

Start: 2017-04-30End: 2023-05-01Target: 60Updated: 2022-08-31

Phase 2

A Multicenter Study Evaluating Efficacy and Safety of 177Lu-DOTA-TATE Based on Kidney-Dosimetry in Patients With Disseminated Neuroendocrine Tumors

CompletedNCT01456078

Lund University HospitalLiver Metastases, Neuroendocrine Tumors

Start: 2011-10-31End: 2018-11-30Updated: 2019-09-30

Related Papers

Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients

European Journal of Nuclear Medicine and Molecular Imaging2022-04-2271 citations

Dose escalation of an Evans blue-modified radiolabeled somatostatin analog <sup>177</sup>Lu-DOTA-EB-TATE in the treatment of metastatic neuroendocrine tumors.

2019-12-1223 citations